164 related articles for article (PubMed ID: 19414111)
1. Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Smaldone MC; Maranchie JK
Urol Oncol; 2009; 27(3):238-45. PubMed ID: 19414111
[TBL] [Abstract][Full Text] [Related]
2. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM
J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia inducible factor (HIF): its central role in renal cell cancer targeted therapy.
Loughlin KR
Urol Oncol; 2009; 27(3):236-7. PubMed ID: 19414110
[No Abstract] [Full Text] [Related]
4. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris MR; Hughes DJ; Tian YM; Ricketts CJ; Lau KW; Gentle D; Shuib S; Serrano-Fernandez P; Lubinski J; Wiesener MS; Pugh CW; Latif F; Ratcliffe PJ; Maher ER
Anticancer Res; 2009 Nov; 29(11):4337-43. PubMed ID: 20032376
[TBL] [Abstract][Full Text] [Related]
5. Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element.
Kageyama Y; Sugiyama H; Ayame H; Iwai A; Fujii Y; Huang LE; Kizaka-Kondoh S; Hiraoka M; Kihara K
Acta Oncol; 2006; 45(3):317-24. PubMed ID: 16644575
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
8. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
9. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
10. mTOR pathway in renal cell carcinoma.
Hanna SC; Heathcote SA; Kim WY
Expert Rev Anticancer Ther; 2008 Feb; 8(2):283-92. PubMed ID: 18279068
[TBL] [Abstract][Full Text] [Related]
11. Transgenic models to understand hypoxia-inducible factor function.
Doedens A; Johnson RS
Methods Enzymol; 2007; 435():87-105. PubMed ID: 17998050
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of renal cortical tumors.
Klatte T; Pantuck AJ
Urol Clin North Am; 2008 Nov; 35(4):573-80; vi. PubMed ID: 18992611
[TBL] [Abstract][Full Text] [Related]
13. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.
Yan Q; Bartz S; Mao M; Li L; Kaelin WG
Mol Cell Biol; 2007 Mar; 27(6):2092-102. PubMed ID: 17220275
[TBL] [Abstract][Full Text] [Related]
14. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC).
Drabkin HA; Gemmill RM
Adv Cancer Res; 2010; 107():39-56. PubMed ID: 20399960
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 in renal carcinoma cells is independent of pVHL.
Stickle NH; Cheng LS; Watson IR; Alon N; Malkin D; Irwin MS; Ohh M
Mutat Res; 2005 Oct; 578(1-2):23-32. PubMed ID: 15998523
[TBL] [Abstract][Full Text] [Related]
16. The silencing approach of the hypoxia-signaling pathway.
Berra E; Pouysségur J
Methods Enzymol; 2007; 435():107-21. PubMed ID: 17998051
[TBL] [Abstract][Full Text] [Related]
17. [Roles and molecular mechanisms of hypoxia-inducible factors in renal cell carcinoma].
Zou JX; Chen K
Yi Chuan; 2018 May; 40(5):341-356. PubMed ID: 29785943
[TBL] [Abstract][Full Text] [Related]
18. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau gene: turning discovery into therapy.
Clark PE; Cookson MS
Cancer; 2008 Oct; 113(7 Suppl):1768-78. PubMed ID: 18800388
[TBL] [Abstract][Full Text] [Related]
20. The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction.
Tanaka T; Wiesener M; Bernhardt W; Eckardt KU; Warnecke C
Biochem J; 2009 Oct; 424(1):143-51. PubMed ID: 19694616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
